The Incidence of Herpes Zoster Complications: A Systematic Literature Review

Giannelos, Nikolaos; Curran, Desmond; Nguyen, Chi; Kagia, Carol; Vroom, Nikki; Vroling, Hilde

doi:10.1007/s40121-024-01002-4

Infect Dis Ther

2024

DOI: 10.1007/s40121-024-01002-4

|View full text |Cite

The Incidence of Herpes Zoster Complications: A Systematic Literature Review

Nikolaos Giannelos,

Desmond Curran,

Chi Nguyen

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 155 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Unlocking the value of Shingrix: how vaccination empowers older adults

Flanagan,

Wood

2024

Microbiol. Aust.

View full text Add to dashboard Cite

Shingles, and its often-debilitating complication post-herpetic neuralgia (PHN), is a common condition, particularly in older populations whose immune systems have declined with age. As the number of older people continues to rise globally, healthy aging becomes an ever-increasing priority from a public health perspective. The recombinant zoster vaccine Shingrix has been shown in clinical trials to have excellent efficacy and provides long-lasting protection even in those with weaker immunity such as the very old. Cost-effectiveness analyses are complex due to the many factors that need to be considered, but many conducted to date support Shingrix vaccination as a cost-effective means of preventing shingles and PHN in the elderly. These studies suggest that Shingrix is superior to the live Zostavax vaccine. Shingrix was approved by the US Food and Drug Administration in October 2017, and the European Medicines Agency and Australian Therapeutic Goods Association in 2018 for the prevention on shingles in adults ≥50 years of age. In 2023, the Pharmaceutical Benefits Advisory Committee (PBAC) recommended funding a Shingrix program in Australia, and it became available on the National Immunisation Program (NIP) that year, whereas the Zostavax vaccine was discontinued. Shingrix is recommended under the Australian NIP for people aged 65 years and over, Aboriginal and Torres Strait Islander people ≥50 years and those ≥18 years with severe immunocompromise. Multiple other countries have funded national Shingrix programs in recent years with similar recommendations. Since its introduction, demand for Shingrix has been high, and uptake is expected to supersede Zostavax uptake.

show abstract

Unlocking the value of Shingrix: how vaccination empowers older adults

Flanagan,

Wood

2024

Microbiol. Aust.

View full text Add to dashboard Cite

show abstract

Earlobe Loss After Herpes Zoster Infection: An Uncommon Complication

Zaouak,

Chamli,

Hammami

et al. 2024

J of Cosmetic Dermatology

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The Incidence of Herpes Zoster Complications: A Systematic Literature Review

Cited by 2 publications

References 155 publications

Unlocking the value of Shingrix: how vaccination empowers older adults

Unlocking the value of Shingrix: how vaccination empowers older adults

Earlobe Loss After Herpes Zoster Infection: An Uncommon Complication

Contact Info

Product

Resources

About